Brief Recent History
NF was manufactured in the 1970s by Bayer -as Lampit®- but its development started earlier, in the 1960s as Bayer-2502. Similar to what happened with BZN, Bayer discontinued production in the 1990s due to low demand and almost null profitability, but reconsidered and restarted production later. Since then, country-level access to the drug has depended on individual states’ agreements and negotiations with WHO and Bayer, and local bureaucratic and political decisions. Availability currently seems erratic in many South American countries, but it is expected to improve in the near future, after a clinical trial performed in children -CHICO study (NCT02625974) - that supported FDA approval of NF formulations for CD in the pediatric population.